Renal handling of matrix gla-protein in humans with moderate to severe hypertension

Hypertension Research

Volumn 31, Issue 9, 2008, Pages 1745-1751

  Rennenebrg, Roger J M W ^a   Schurgers, Leon J ^b   Vermeer, Cees ^b   Scholte, Jan B J ^a   Houben, Alphons J H M ^a   de Leeuw, Peter W ^a   Kroon, Abraham A ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Blood flow; Calcification; Hypertension; Matrix Gla protein; Renal clearance

Indexed keywords

CREATININE; MATRIX GLA PROTEIN; MATRIX PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTERIAL BLOOD; ARTICLE; BLOOD SAMPLING; CIRCULATION; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE SEVERITY; FEMALE; HUMAN; HYPERTENSION; KIDNEY ANGIOGRAPHY; KIDNEY ARTERY STENOSIS; KIDNEY CLEARANCE; MAJOR CLINICAL STUDY; MALE; VENOUS BLOOD;

EID: 55449104039     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.31.1745     Document Type: Article

References (31)

1. Fogteloo AJ, Meinders AE, Pijl H, Kroon AA, Frolich M, De Leeuw PW: Renal clearance of endogenous leptin in hypertensive humans with or without renal artery stenosis. Am J Physiol Endocrinol Metab 2001; 281: E400-E404.
2. Buijs MM, de Leeuw PW, Houben AJ, et al: Renal contribution to increased clearance of exogenous growth hormone in obese hypertensive patients. J Clin Endocrinol Metab 2005; 90: 795-799.
3. Price PA, Urist MR, Otawara Y: Matrix Gla protein, a new gamma-carboxyglutamic acid-containing protein which is associated with the organic matrix of bone. Biochem Biophys Res Commun 1983; 117: 765-771.
4. Luo G, Ducy P, McKee MD, et al: Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997; 386: 78-81.
5. Dhore CR, Cleutjens JP, Lutgens E, et al: Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2001; 21: 1998-2003.
6. Price PA, Faus SA, Williamson MK: Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol 1998; 18: 1400-1407.
7. Farzaneh-Far A, Davies JD, Braam LA, et al: A polymorphism of the human matrix gamma-carboxyglutamic acid protein promoter alters binding of an activating protein-1 complex and is associated with altered transcription and serum levels. J Biol Chem 2001; 276: 32466-32473.
8. Shanahan CM, Cary NR, Metcalfe JC, Weissberg PL: High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. J Clin Invest 1994; 93: 2393-2402.
9. Price PA, Thomas GR, Pardini AW, Figueira WF, Caputo JM, Williamson MK: Discovery of a high molecular weight complex of calcium, phosphate, fetuin, and matrix gamma-carboxyglutamic acid protein in the serum of etidronate-treated rats. J Biol Chem 2002; 277: 3926-3934.
10. Braam LA, Dissel P, Gijsbers BL, et al: Assay for human matrix Gla protein in serum: potential applications in the cardiovascular field. Arterioscler Thromb Vasc Biol 2000; 20: 1257-1261.
11. Jono S, Ikari Y, Vermeer C, et al: Matrix Gla protein is associated with coronary artery calcification as assessed by electron-beam computed tomography. Thromb Haemost 2004; 91: 790-794.
12. Schurgers LJ, Teunissen KJ, Knapen MH, et al: Characteristics and performance of an immunosorbent assay for human matrix Gla-protein. Clin Chim Acta 2005; 351: 131-138.
13. Hermans MM, Vermeer C, Kooman JP, et al: Undercarboxylated matrix GLA protein levels are decreased in dialysis patients and related to parameters of calcium-phosphate metabolism and aortic augmentation index. Blood Purif 2007; 25: 395-401.
14. Cetin M, Cetin R, Tamer N: Prevalence of breast arterial calcification in hypertensive patients. Clin Radiol 2004; 59: 92-95.
15. Anderson GH Jr, Blakeman N, Streeten DH: Prediction of renovascular hypertension. Comparison of clinical diagnostic indices. Am J Hypertens 1988; 1: 301-304.
16. Krijnen P, van Jaarsveld BC, Steyerberg EW, Man in 't Veld AJ, Schalekamp MA, Habbema JD: A clinical prediction rule for renal artery stenosis. Ann Intern Med 1998; 129: 705-711.
17. Detection, evaluation, and treatment of renovascular hypertension. Final report. Working Group on Renovascular Hypertension. Arch Intern Med 1987; 147: 820-829.
18. de Leeuw PW, Birkenhager WH: Use of the xenon-133 washout technique in diagnosing renovascular disease in hypertension. Nephron 1986; 44 (Suppl 1): 5-7.
19. Ladefoged J: Measurements of the renal blood flow in man with the 133 xenon wash-out technique. A description of the method. Scand J Clin Lab Invest 1966; 18: 299-315.
20. Wierema TK, Houben AJ, Kroon AA, et al: Nitric oxide dependence of renal blood flow in patients with renal artery stenosis. J Am Soc Nephrol 2001; 12: 1836-1843.
21. van Onna M, Houben AJ, Kroon AA, et al: Asymmetry of renal blood flow in patients with moderate to severe hypertension. Hypertension 2003; 41: 108-113.
22. Koyama N, Ohara K, Yokota H, et al: A one step sandwich enzyme immunoassay for gamma-carboxylated osteocalcin using monoclonal antibodies. J Immunol Methods 1991; 139: 17-23.
23. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
24. De Leeuw PW, Birkenhäger WH: Use of the xenon-133 washout technique in diagnosing renovascular disease in hypertension. Nephron 1986; 44: 5-7.
25. Fraser JD, Price PA: Lung, heart, and kidney express high levels of mRNA for the vitamin K-dependent matrix Gla protein. Implications for the possible functions of matrix Gla protein and for the tissue distribution of the gamma-carboxylase. J Biol Chem 1988; 263: 11033-11036.
26. Cancela ML, Price PA: Retinoic acid induces matrix Gla protein gene expression in human cells. Endocrinology 1992; 130: 102-108.
27. Cancela ML, Hu B, Price PA: Effect of cell density and growth factors on matrix GLA protein expression by normal rat kidney cells. J Cell Physiol 1997; 171: 125-134.
28. Price PA, Williamson MK, Lothringer JW: Origin of the vitamin K-dependent bone protein found in plasma and its clearance by kidney and bone. J Biol Chem 1981; 256: 12760-12766.
29. Ivaska KK, Kakonen SM, Gerdhem P, Obrant KJ, Pettersson K, Vaananen HK: Urinary osteocalcin as a marker of bone metabolism. Clin Chem 2005; 51: 618-628.
30. Ivaska KK, Pettersson K, Nenonen A, et al: Urinary osteocalcin is a useful marker for monitoring the effect of alendronate therapy. Clin Chem 2005; 51: 2362-2365.
31. Demer LL, Tintut Y: Mineral exploration: search for the mechanism of vascular calcification and beyond: the 2003 Jeffrey M. Hoeg Award lecture. Arterioscler Thromb Vasc Biol 2003; 23: 1739-1743.